MI-ER1α and Breast Cancer Progression
Author Information
Author(s): McCarthy P L, Mercer F C, Savicky M W J, Carter B A, Paterno G D, Gillespie L L
Primary Institution: Memorial University of Newfoundland
Hypothesis
Does the subcellular localization of MI-ER1α influence breast cancer progression?
Conclusion
The shift from nuclear to cytoplasmic localization of MI-ER1α during breast cancer progression suggests that loss of nuclear MI-ER1α might contribute to the development of invasive breast carcinoma.
Supporting Evidence
- MI-ER1α interacts with ERα in both the presence and absence of estrogen.
- Overexpression of MI-ER1α inhibits estrogen-stimulated growth in breast carcinoma cells.
- Nuclear MI-ER1α was found in 75% of normal breast samples but only in 4% of invasive ductal carcinoma samples.
Takeaway
This study found that a protein called MI-ER1α changes its location in breast cancer cells, which might help cancer grow.
Methodology
The study used co-immunoprecipitation assays, functional analysis in cell lines, and immunohistochemical analysis of tissue samples.
Limitations
The study did not distinguish between the two MI-ER1 isoforms and relied on a limited number of cases for some analyses.
Participant Demographics
The study examined 110 cases of primary invasive ductal carcinoma from a cancer registry.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95%
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website